tldrdailynews.com logo

Zealand Pharma Soars on Positive Weight-Loss Drug Trial Results

1 min read
Source: Quartz
Zealand Pharma Soars on Positive Weight-Loss Drug Trial Results
Photo: Quartz
TL;DR

Zealand Pharma's stock rose 17% after announcing that its experimental weight loss drug petrelintide showed similar efficacy to Ozempic with fewer side effects in a phase 1 trial. Petrelintide, a long-acting amylin analog, could be an alternative for patients who can't tolerate GLP-1 treatments.

Topics:businesshealth#clinical-trial#glp-1#health#petrelintide#weight-loss#zealand-pharma
Share this article
  1. Zealand Pharma stock surges 23% on results for its Ozempic alternative  Quartz
  2. Weight loss drug contender Zealand Pharma jumps 18% on trial results  CNBC
  3. What To Know About Zealand Pharma's Petrelintide—An Ozempic Competitor  Forbes
  4. Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s  MarketWatch
  5. Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide  Yahoo Finance

Want the full story? Read the original reporting

Read on Quartz